Amylyx Pharmaceuticals Strengthens Board of Directors with Appointment of Daphne Quimi, Chief Financial Officer of Amicus Therapeutics

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. today announced the addition of Daphne Quimi to its Board of Directors. Ms. Quimi brings more than 25 years of executive experience in the pharmaceutical and biotechnology industries with expertise in global finance operations, company building, and rare disease drug commercialization. She currently serves as Chief Financial Officer (CFO) of Amicus Therapeutics.

“We seek the strongest, most experienced, and patient-centric industry professionals to join our Board of Directors to help Amylyx serve people living with ALS and other neurodegenerative diseases around the world. Daphne is the epitome of these qualities and more and will be a valuable advisor as we seek to advance our pipeline,” said Joshua Cohen, Co-CEO, Chairman and Co-Founder of Amylyx. “Daphne’s longtime financial leadership and acumen, combined with her dedication at Amicus to helping people living with rare diseases around the world, make her a wonderful addition to our Board. On behalf of the entire Amylyx team, we are thrilled to welcome her,” added Justin Klee, Co-CEO and Co-Founder of Amylyx.

Ms. Quimi joined Amicus in 2007 where she is currently the CFO, responsible for directing all financial activities, including strategic planning, financial reporting and budgeting, investor relations and shareholder engagement. Ms. Quimi joined Amicus when it was a pre-commercial company and has the experience of helping build Amicus through its first regulatory approvals and launches for Galafold™ in the U.S., Europe, Canada and Japan.

“I am delighted to join the board of a truly patient-centric company that is providing hope and dedicated to advancing its promising investigational product, particularly given its statistically significant benefit in function and survival in people with ALS,” said Ms. Quimi. “I look forward to working with this dynamic and driven leadership team as the company grows and builds globally to help people around the world living with neurodegenerative diseases.”

Prior to her roles at Amicus, Ms. Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb and held roles of increasing responsibility in the finance division at Johnson & Johnson. She has also served as an auditor at KPMG. Ms. Quimi received a B.S. in Accountancy from Monmouth University in New Jersey and an MBA from the Stern School of Business of New York University.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is a pharmaceutical company working on developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases. For more information, visit www.amylyx.com and follow us on LinkedIn and Twitter.

Contacts

Merissa Muller

Finn Partners

(617) 778-6633

Merissa.Muller@finnpartners.com